Compare Stocks: APM, CYCN, CTXR, and CALC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
CALC CalciMedica	$2.30 +13.9%	$3.42	$1.91 ▼ $36.00	$13.79M	0.83	92,442 shs	181,619 shs
CTXR Citius Pharmaceuticals	$0.58 -3.4%	$0.59	$0.47 ▼ $2.19	$16.49M	1	671,814 shs	76,509 shs
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$25.97	$1.03 ▼ $8.48	$15.73M	1.75	96,117 shs	435,914 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-92.49%	-96.29%
CALC CalciMedica	+13.86%	+9.52%	-30.20%	-48.40%	-87.15%
CTXR Citius Pharmaceuticals	-3.41%	+0.09%	-14.33%	+1.29%	-52.07%
CYCN Cyclerion Therapeutics	-85.16%	-88.97%	-86.07%	-84.47%	-80.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
CALC CalciMedica	$2.30 +13.9%	$3.42	$1.91 ▼ $36.00	$13.79M	0.83	92,442 shs	181,619 shs
CTXR Citius Pharmaceuticals	$0.58 -3.4%	$0.59	$0.47 ▼ $2.19	$16.49M	1	671,814 shs	76,509 shs
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$25.97	$1.03 ▼ $8.48	$15.73M	1.75	96,117 shs	435,914 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-92.49%	-96.29%
CALC CalciMedica	+13.86%	+9.52%	-30.20%	-48.40%	-87.15%
CTXR Citius Pharmaceuticals	-3.41%	+0.09%	-14.33%	+1.29%	-52.07%
CYCN Cyclerion Therapeutics	-85.16%	-88.97%	-86.07%	-84.47%	-80.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	1.00	Sell	N/A	N/A
CALC CalciMedica	2.20	Hold	$50.00	2,073.91% Upside
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	762.07% Upside
CYCN Cyclerion Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest APM, CYCN, CTXR, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/24/2026	CYCN Cyclerion Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	9.86	N/A	N/A	$2.17 per share	0.31
CALC CalciMedica	N/A	N/A	N/A	N/A	($2.30) per share	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
CYCN Cyclerion Therapeutics	$2.07M	7.89	N/A	N/A	$2.31 per share	1.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$1.36M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
CYCN Cyclerion Therapeutics	-$3.53M	-$1.66	N/A	N/A	N/A	-170.11%	-87.96%	-74.86%	11/11/2026 (Estimated)

Latest APM, CYCN, CTXR, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A
8/4/2026	Q2 2026	CYCN Cyclerion Therapeutics	-$49.70	-$2.87	+$46.83	-$0.41	$1.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.78	0.78
CALC CalciMedica	1.67	5.58	5.58
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
CYCN Cyclerion Therapeutics	N/A	0.82	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CALC CalciMedica	N/A
CTXR Citius Pharmaceuticals	16.88%
CYCN Cyclerion Therapeutics	75.62%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CALC CalciMedica	28.25%
CTXR Citius Pharmaceuticals	4.99%
CYCN Cyclerion Therapeutics	34.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	6.35 million	2.29 million	Not Optionable
CALC CalciMedica	30	6.83 million	4.90 million	No Data
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
CYCN Cyclerion Therapeutics	30	4.68 million	3.08 million	No Data

APM, CYCN, CTXR, and CALC Headlines

Recent News About These Companies

Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

September 8 at 4:05 PM | globenewswire.com

Cyclerion Therapeutics (NASDAQ:CYCN) Shares Scheduled to Reverse Split on Wednesday, September 9th

September 5, 2026 | americanbankingnews.com

Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline

April 21, 2026 | finance.yahoo.com

Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?

April 2, 2026 | finance.yahoo.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

April 2, 2026 | prnewswire.com

Cyclerion to combine with Korsana Biosciences in $380 million merger deal

April 2, 2026 | msn.com

Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public

April 2, 2026 | fiercebiotech.comF

Cyclerion provides public listing vehicle for Korsana in $380M deal

April 2, 2026 | bizjournals.com

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

April 2, 2026 | businesswire.com

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

April 1, 2026 | prnewswire.com

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

April 1, 2026 | seekingalpha.com

Cyclerion Therapeutics (CYCN) Stock Jumps 160% Following Korsana Biosciences Merger Announcement

April 1, 2026 | blockonomi.com

CYCN stock is soaring 150% pre-market today — what is fueling the rally?

April 1, 2026 | msn.com

Cyclerion Soars Over 160% After Announcing Merger With Korsana Biosciences

April 1, 2026 | rttnews.com

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

April 1, 2026 | businesswire.com

Cyclerion Therapeutics (CYCN) price target increased by 100.00% to 8.16

February 26, 2026 | msn.com

CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26

February 23, 2026 | finance.yahoo.com

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

February 17, 2026 | globenewswire.com

CYCN: Engineering a reset; initiating coverage of Cyclerion Therapeutics

February 4, 2026 | msn.com

CYCN: Engineering a Reset; Initiating Coverage of Cyclerion Therapeutics…

February 2, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, CYCN, CTXR, and CALC Company Descriptions

Aptorum Group NASDAQ:APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

CalciMedica NASDAQ:CALC

$2.30 +0.28 (+13.86%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$2.24 -0.06 (-2.57%)

As of 09/9/2026 07:57 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Citius Pharmaceuticals NASDAQ:CTXR

$0.58 -0.02 (-3.41%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$0.58 +0.01 (+0.86%)

As of 09/9/2026 07:47 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Cyclerion Therapeutics NASDAQ:CYCN

$3.49 +0.13 (+3.87%)

Closing price 09/8/2026 07:42 PM Eastern

Extended Trading

$3.49 0.00 (0.00%)

As of 09/8/2026 07:42 PM Eastern

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, CYCN, CTXR, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, CYCN, CTXR, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, CYCN, CTXR, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, CYCN, CTXR, and CALC Company Descriptions

Aptorum Group NASDAQ:APM

CalciMedica NASDAQ:CALC

Citius Pharmaceuticals NASDAQ:CTXR

Cyclerion Therapeutics NASDAQ:CYCN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, CYCN, CTXR, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, CYCN, CTXR, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, CYCN, CTXR, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, CYCN, CTXR, and CALC Company Descriptions

Aptorum Group NASDAQ:APM

CalciMedica NASDAQ:CALC

Citius Pharmaceuticals NASDAQ:CTXR

Cyclerion Therapeutics NASDAQ:CYCN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools